Intelligence · Clinical Pipeline
AbbVie Deutschland GmbH Pipeline
All ClinicalTrials.gov programs at AbbVie Deutschland GmbH — phase, modality, and trial IDs.
- Programs
- 4
Quick answer
AbbVie Deutschland GmbH has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
ABBV-066, DEUCRAVACITINIB
AbbVie Deutschland GmbH & Co. KG
Plaque Psoriasis
1 trial -
DUPILUMAB, Upadacitinib, Upadacitinib
AbbVie Deutschland GmbH & Co. KG
Atopic Dermatitis
1 trial -
Ibrutinib
AbbVie Deutschland GmbH & Co. KG
1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom macroglobulinemia 4. Multiple Myeloma 5. Marginal Zone Lymphoma 6. Diffuse Large B-Cell Lymphoma 7. Urothelial Carcinoma 8. Breast Cancer 9. Acute Myeloid Leukemia 10. Graft vs Host Disease 11. Mantle Cell Lymphoma
1 trial -
Surabgene Lomparvovec (ABBV-RGX-314), Lucentis 10 mg/ml solution for injection in pre-filled syringe, Surabgene Lomparvovec (ABBV-RGX-314)
AbbVie Deutschland GmbH & Co. KG
Neovascular age-related macular degeneration
1 trial
Frequently asked questions
How many pipeline programs does AbbVie Deutschland GmbH have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs